Articles On Optiscan Imaging (ASX:OIL)

Momentum investing involves taking advantage of, and making profits from, upward trends in a stock. The strategy makes a calculated bet that the stock market’s recent winners will remain winners. William J. O’Neil, the founder of Investor’s...

Medical device manufacturer Optiscan Imaging has expanded its U.S push, opening an office in the biotech hub of Minnesota with two well-credentialed hires.

The ASX200 ends Tuesday slightly lower Resources stocks hold the fort, everyone else AWOL  Small Caps led by Dart Mining and Mesoblast   Local stocks looked the goods during the first hour of the new quarter, but that – like the ASX200’s...

Special Report: Optiscan is beefing up its presence in the US as it works toward securing US regulatory approvals for its confocal endomicroscopic imaging technologies.  Optiscan (ASX:OIL) has started to ramp up its presence in the US after...

Optiscan Imaging (ASX:OIL) has announced the establishment of its US Regional Office in Rochester, Minnesota, and the appointment of two US-based heads of clinical and regulatory affairs.

Optiscan Imaging’s ongoing studies aimed at producing revolutionary medical imaging devices have received a timely financial boost through a $672,320 research and development tax rebate from the ATO.

ASX Health Index down -1.5% for February 76 biotechs rose, and 78 fell during the month But essentially, biotech is a long term game for investors   The S&P/ASX 200 Health Care [XHJ] struggled in February, finishing -1.5% lower and tr...

Viking Therapeutics doubled after results of weight loss drug trial Janux Therapeutics tripled on pancreatic cancer results We look at the recent best performing ASX health stocks   There were a couple of big news from the world of biotec...

Early detection and effective treatment can lead to remission or cure for many cancers Optiscan’s tech brings surgeons and pathologists together to better diagnose, treat and monitor cancer Race Oncology’s working to minimise cardiovascula...

Stockhead’s Ashtyn Hiron sits down with Optiscan (ASX:OIL) CEO And Managing Director Dr. Camile Farah to get the short end of the long story on the company’s latest news. Optiscan received a $3 million dollar grant to work on its second-gen...

US inflation data came in higher than tipped, rattling the markets over there, with the ripple effect expected to reach the ASX200 today. Futures predict the local share market will shed 1.5 per cent for Valentine’s Day. The Nasdaq tu...

Optiscan Imaging is investigating how it can use AI in the cancer-fighting technology it believes could help create a multi-billion-dollar revenue stream in the United States, after receiving a $3m grant.

A money trail is forming behind Optiscan Imaging’s technology-based mission to tackle the scourge of cancer, with revenue starting to stream into the company’s coffers from the lucrative Chinese health sector.

Optiscan’s platform could help with shortage of pathologists in Australia and globally Platform particularly useful in diagnosing malignant tumours and pre-cancerous lesions in surgery Optiscan seeking US FDA De Novo clearance for its InV...

Xi and Biden set to agree on restricting fentanyl  Fentanyl is a synthetic opioid responsible for the opioids epidemic in the US We look at the best performing health stocks over the past couple of weeks   China’s President Xi is expected...

Stockhead’s In-Case-You-Missed-It highlights today’s most interesting small cap stories that might have slipped beneath your radar. Below is a wrap of the top 20 performing stocks, by percentage, which made announcements today.   ICYMI Lead...

News relating to Novo Nordisk’s Ozempic has led to a selloff in some ASX stocks CSL, FPH, and RMD fell heavily last week But Goldman analysts say they won’t change ratings on these 3 stocks   Goldman Sachs analysts said they will make no...

Optiscan Imaging has strengthened its mission aimed at breaking into the US health market or with its “ViewnVivo” technology by putting key personnel on the ground on that country’s east and west coasts.

L’Oréal to take minority stake in Chinese startup Shinehigh Innovation Shinehigh is developing supramolecular technology which could be used in the fashion industry Best and worst performing ASX biotechs over the past couple of weeks   Be...

Optiscan Imaging is on a mission to prove its technology can provide surgeons with the exact extent of breast cancer margins at the time of operating through the real-time diagnosis of affected tissues.

Optiscan Imaging (ASX:OIL) has provided an interim readout on its Breast Cancer Intraoperative Assessment Study.

The FDA has just approved an emergency use authorisation for new Covid-19 vaccines What is emergency use authorisation, and which ASX stocks have got it? We look at the best and worst performing ASX biotechs over the couple of weeks   On...

Earnings reports dominated headlines in August Despite solid results from ASX healthcare giants, the sector finished lower We take a look at which ASX healthcare stocks performed the best in August   August was all about earnings, and des...

Australian biotech has attracted US investments in the last five years Among ASX stocks to get funded from the US include Opthea We look at the  best and worst performing ASX biotechs over the past month   The Australian biotech sector co...

Biotech could be a US$4 trillion industry in 10 years Genetic engineering and weight loss are two growing themes in the space We look at the best and worst performing ASX biotechs over the past month   Steve Jobs used to say that the most...

Optiscan Imaging has ticked off a major milestone in developing its telepathology platform, with the project passing its proof-of-concept stage amid plans for the software to completed by the end of next year.

The end of pandemic and higher rates have subdued biotech market But there are signs now the sector is making a comeback We take a look at the ASX Biotech Winners in July   The Covid-19 pandemic had produced windfalls for and attracted fa...

Optiscan Imaging says it has successfully raised $16.7 million from a recent entitlement issue as the company looks to pursue research and development projects, in addition to developing new clinical devices.

Optiscan Imaging has been invited to present its remarkable confocal endomicroscopic medical imaging technology at two key international conferences in North and South America.

Brisbane-based biotech Vaxxas is working on needles-free vaccine The Nanopatch is said to be a “game changer” We look at the best and worst performing ASX biotechs over the past month   The world is anticipating a “game changer” as Brisba...

Small cap health stocks are not known to pay dividends But there’s a handful of such stocks on the ASX that do pay dividends We look at the best and worst performing ASX biotechs over the past week   When we talk about dividend-paying hea...

Biotech is making a comeback in 2023 There’s been a couple of breakthroughs on the ASX this year We take a look at the ASX biotech winners in May   There are clear signs the biotech sector is springing back to life after a disappointing 2...

Optiscan Imaging (ASX:OIL) has launched an entitlement offer to raise $16.7 million it says will be used to support its strategic portfolio expansion.

Optiscan Imaging has revealed a $16.7 million mission to fast-track the development of its revolutionary medical imagery devices. An entitlement offer has already been supported by two cornerstone investors.

Optiscan Imaging (ASX:OIL) has announced the publication of readout results of its oral cancer imaging study conducted by Dr Camile Farah and his team at the Australian Centre for Oral Oncology Research and Education.

Artificial intelligence is set to disrupt the healthcare sector AI could also help in drugs discovery Telix delivers first quarterly revenue of $100 million   Moody’s Analytics’ chief economist, Mark Zandi, said the healthcare industry’s...

Australian company Optiscan Imaging (ASX:OIL) has announced the establishment of a new commercial operation in the US.

The medical imaging market size globally is forecast to reach $68.8 Billion by 2030 Several ASX health imaging stocks are establishing strong footholds and niches in sector Micro-X branching out from the medical sphere with its bomb detect...

Several ASX health stocks are seeking US FDA approval for drugs/devices in the near future Telix Pharmaceuticals is chasing renal cancer imaging approval for TLX-250 CDx Aroa is awaiting an FDA decision on the required regulatory pathway...

Optiscan Imaging (ASX:OIL) has announced the interim results of its oral imaging study conducted at the Australian Centre for Oral Oncology Research and Education.

Patrys says pre-clinical data supports its drug’s synthetic lethality mechanism Alterity granted patent in the US Optiscan says 100% of cancer cases were diagnosed correctly using its device   Patrys’ PAT-DX3 shown to have ‘synthetic leth...

A recent Optiscan Imaging (OIL) study shows the company’s technology is “extremely accurate” for the diagnosis of oral cancer and precancer The company has received interim results from its oral imaging study, where 47 patients were asse...

US bank stocks were rattled on concerns of a contagion from SVB collapse Bond yields tumbled, lifting rates sensitive shares like Tech Gold continues its climb on flight to safety   It was a volatile session on Wall Street overnight as co...

Optiscan Imaging has announced an exclusive collaboration with Canadian-based Prolucid Technologies to develop AI algorithms and telepathology workflows using its confocal laser endomicroscopy technology.

The FDA declined regulate CBD-based supplements and food, citing safety reasons CBD products have grown exponentially in the marketplace We take a look at what it all means for the cannabis industry   The US FDA announced last week that:...

Optiscan Imaging (OIL) partners with software developer Prolucid Technologies to develop AI algorithms using confocal laser endomicroscopy (CLE) tech The companies will work to develop a processing pipeline to display the results of an A...

Japanese startup OUI is on a mission to halve the world’s blindness with its smartphone-based device Which ASX healthcare companies also have smartphone-based products? A quick look at the best and worst ASX healthcare stocks over the past...

ASX 200 holds steady around +0.8% since lunch Australian Pacific Coal CEO David Conry has left the company. Abruptly. Bain Capital making all the right noises about bringing Virgin back to the bourse   All up, it’s been a pretty tidy old...

ASX 200 edges higher,  small cap index falls 0.44% 7 out of 11 sectors were in the green with Tech up 1.25% Downbeat RBA Governor speech highlights all the things that could go wrong with the economy   Last night the leads were decent, th...

ASX health stocks have been out of favour this year with rotation away from growth to value sector Morgan’s Scott Power said a lot of biotechs aren’t able to convert their complex science into layman’s terms Hot money going to lithium and...